Does my GLP-1 dose have to keep increasing to keep working? Usually not. The registration trials titrated patients to a working dose and then held it for the remainder of the study and the weight loss continued on a flat dose for more than a year. A dose increase is justified when the result has stalled, the labs agree that the stall is real and the side effects allow it. It is not a scheduled event and it is not something your bill should be attached to. Here is how to tell the difference between a dose that needs to move and a titration schedule that moves for other reasons.

Key takeaways
  • The trials held patients at a fixed maintenance dose for 68 to 72 weeks and the loss continued without further increases.
  • A step up is a clinical decision made on stalled results, labs and tolerability, never a calendar event.
  • Plateaus are usually managed by reviewing the panel, protein and training before touching the dose.
  • Our fee is a flat $299 a month at any dose, so a titration decision has no financial vote on our side.
  • The pharmacy bills the medication at its own cost, separate from the fee, always.

What the trials actually did with the dose

In STEP-1, participants on semaglutide 2.4 mg weekly lost about 15 percent of body weight on average over 68 weeks. In SURMOUNT-1, participants on tirzepatide lost up to about 22.5 percent over 72 weeks. In both trials the titration period was a matter of weeks to a few months and the working dose was then held for the remainder of the study. The weight kept coming off on the flat dose. That is the strongest evidence we have that a GLP-1 dose does not need to climb for the result to continue.

What the trials did not include is a dose minimization arm, so the minimum effective dose that works was never established by anyone whose business model would have funded the question. Clinical practice fills that gap with judgment and the quality of that judgment depends on whether the practice profits from the answer.

The three legitimate reasons a dose moves up

Honest medicine does escalate doses sometimes and pretending otherwise would be its own kind of dishonesty. Three situations justify a step.

  1. The result has genuinely stalled. Not a four week fluctuation but a real plateau, confirmed at a ninety day review, with weight and waist and the metabolic panel all agreeing that progress stopped.
  2. The panel supports it. HbA1c or fasting insulin moving the wrong way despite adherence or a new finding that changes the clinical picture.
  3. Tolerability allows it. Side effects are quiet and the patient wants more of a result the current dose is not delivering.

When all three are true, a step up is good medicine. When only the calendar supports it, the schedule is serving somebody other than the patient.

Clinical note

A dose increase should be an answer to a clinical question, never a subscription renewal.

What to do at a plateau before touching the dose

Most plateaus are not dose problems. The first pass at a stall is a workup and the sequence looks like this.

  • Read the panel. At the next Biomarker Audit the clinician reads HbA1c, fasting insulin, hs-CRP, the lipid panel and the thyroid line against the plateau. A thyroid drifting the wrong way or an insulin climbing explains stalls that no dose change would fix.
  • Audit the protein. Appetite suppression quietly removes protein from the diet and lean mass follows. If protein intake fell below what the muscle needs, the scale will stall even while fat is still leaving.
  • Check the training stimulus. A program that stopped being a challenge stopped producing a result.
  • Give it one more cycle. Bodies adapt and water shifts. Holding the dose for one more ninety day review before escalating is rarely the wrong move.

If the panel is clean, the protein is adequate and the training is real and the result is still stalled, then the dose conversation is legitimate. It should also be free of any price change on our side, because it is.

GoodLife Health. Medicine that builds on itself, $299 a month: 90-day labs, your clinician, branded GLP-1s, one platform. See if you qualify.GoodLife Health. $299 a month. Everything talks to everything: quarterly labs read by your clinician, branded GLP-1s prescribed from them, every result and dose tracked on one platform. See if you qualify.

Why the fee never rises with the dose

One flat fee for the doctor. Zero markup on the medicine. The structure exists because the titration is where the industry's conflict lives. On most weight loss platforms the monthly price rises at each step of the ladder, so the platform books revenue every time the dose climbs. In that model the next step is always the profitable answer and the clinician who recommends holding the dose is recommending against the business.

Our model separates the two charges so the conflict cannot exist. The membership is one flat $299 per month for the clinical relationship and four Biomarker Audits a year. It starts with a two month commitment paid as a single $598 charge covering the first two months together, including the intake and the first audit. From month three it is month to month and you can cancel anytime. Any prescription is written to the pharmacy you choose and billed by that pharmacy at its own cost. GoodLife Health sets nothing, sees nothing and takes nothing on the medication. If your dose goes down, our revenue does not change. If it goes up, our revenue does not change.

The questions that expose a dose-linked program

Before joining any program, three questions separate medicine from a ladder. First, what was the dose at your last review and what did the panel say? A program that cannot answer has no protocol. Second, when was the last time a dose came down for anyone? A titration that only climbs was never measuring the floor. Third, who earns more when the dose goes up? If the program does, every future titration conversation already has its answer.

The honest answers here are published deliberately. The dose holds when the result holds. The floor gets tested with planned reductions and rechecks. And nobody at GoodLife Health earns a dollar more when your dose climbs, because the revenue sits in the fee and the fee is flat.

Who this is not for

If you want the maximum dose the market will sell regardless of the panel, our clinicians will not lead with that. If you want compounded vials, we prescribe branded, FDA-approved medication only, Wegovy, Zepbound, Ozempic, Mounjaro, Wegovy Tablets and Foundayo where appropriate and never compounded. If you want a prescription in the first conversation without labs, the Biomarker Audit comes first and we will not skip it.

Frequently Asked Questions

Does my GLP-1 dose have to keep increasing to keep working?

Usually not. The trials held patients at a fixed dose for 68 to 72 weeks and the weight loss continued. A step up is justified when the result has stalled at a ninety day review, the labs agree and tolerability allows it.

What should happen at a plateau before a dose increase?

A workup. The panel gets read against the stall, protein intake gets checked, the training stimulus gets reviewed and one more ninety day cycle is often enough. A dose change comes after that, if the evidence supports it.

How long can you stay on one GLP-1 dose?

For as long as it keeps working and the quarterly panel stays clean. The SELECT trial followed semaglutide patients for roughly four years with no new duration related safety signal. Duration is a clinical decision reviewed every 90 days.

Does a dose increase cost more at GoodLife Health?

No. The membership is a flat $299 per month at any dose, with a two month commitment to start paid as a single $598 charge covering the first two months. The medication is billed by the pharmacy at its own cost, separate from the fee.

Why do other programs raise the price when the dose rises?

Because the titration is where their revenue lives. When the monthly price is attached to the dose ladder, the next step is always the profitable move. Separating the fee from the medicine removes that incentive, which is why our structure is built the way it is.

What if my dose needs to come down?

Then it comes down deliberately, with a planned reduction and a recheck at the following Biomarker Audit. The fee stays $299. Testing the floor is part of finding the lowest effective dose and it costs nothing on our side.

Do you prescribe compounded GLP-1?

Never. We prescribe branded, FDA-approved medication only. Compounded GLP-1 carries a different risk profile and we will not prescribe it.

One last thing

The dose ladder is where the money lives in this industry and the honest question to bring to any program is who earns more when your dose climbs. If the answer is the program, the titration has a silent vote in it. If the fee is flat, the dose can follow the medicine instead of the business model.

Related Guides

References

  1. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP-1), New England Journal of Medicine, 2021. doi.org/10.1056/NEJMoa2032183
  2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1), New England Journal of Medicine, 2022. doi.org/10.1056/NEJMoa2107519
  3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT), New England Journal of Medicine, 2023. PubMed 37952131
  4. FDA, medications containing semaglutide marketed for type 2 diabetes or weight loss. fda.gov